TY - JOUR
T1 - Decreasing central line-associated bloodstream infections rates in intensive care units in 30 low- and middle-income countries
T2 - An INICC approach
AU - Rosenthal, Victor D.
AU - Jin, Zhilin
AU - Brown, Eric C.
AU - Dongol, Reshma
AU - De Moros, Daisy A.
AU - Alarcon-Rua, Johana
AU - Perez, Valentina
AU - Stagnaro, Juan P.
AU - Alkhawaja, Safaa
AU - Jimenez-Alvarez, Luisa F.
AU - Cano-Medina, Yuliana A.
AU - Valderrama-Beltran, Sandra L.
AU - Henao-Rodas, Claudia M.
AU - Zuniga-Chavarria, Maria A.
AU - El-Kholy, Amani
AU - Agha, Hala
AU - Sahu, Suneeta
AU - Mishra, Shakti B.
AU - Bhattacharyya, Mahuya
AU - Kharbanda, Mohit
AU - Poojary, Aruna
AU - Nair, Pravin K.
AU - Myatra, Sheila N.
AU - Chawla, Rajesh
AU - Sandhu, Kavita
AU - Mehta, Yatin
AU - Rajhans, Prasad
AU - Abdellatif-Daboor, Mohammad
AU - Chian-Wern, Tai
AU - Gan, Chin Seng
AU - Mohd-Basri, Mat Nor
AU - Aguirre-Avalos, Guadalupe
AU - Hernandez-Chena, Blanca E.
AU - Sassoe-Gonzalez, Alejandro
AU - Villegas-Mota, Isabel
AU - Aleman- Bocanegra, Mary C.
AU - Bat-Erdene, Ider
AU - Carreazo, Nilton Y.
AU - Castaneda-Sabogal, Alex
AU - Janc, Jarosław
AU - Hlinkova, Sona
AU - Yildizdas, Dincer
AU - Havan, Merve
AU - Koker, Alper
AU - Sungurtekin, Hulya
AU - Dinleyici, Ener C.
AU - Guclu, Ertugrul
AU - Tao, Lili
AU - Memish, Ziad A.
AU - Yin, Ruijie
N1 - Publisher Copyright:
© 2023 Association for Professionals in Infection Control and Epidemiology, Inc.
PY - 2024/5
Y1 - 2024/5
N2 - Background: Central line (CL)-associated bloodstream infections (CLABSIs) occurring in the intensive care unit (ICU) are common and associated with a high burden. Methods: We implemented a multidimensional approach, incorporating an 11-element bundle, education, surveillance of CLABSI rates and clinical outcomes, monitoring compliance with bundle components, feedback of CLABSI rates and clinical outcomes, and performance feedback in 316 ICUs across 30 low- and middle-income countries. Our dependent variables were CLABSI per 1,000-CL-days and in-ICU all-cause mortality rates. These variables were measured at baseline and during the intervention, specifically during the second month, third month, 4 to 16 months, and 17 to 29 months. Comparisons were conducted using a two-sample t test. To explore the exposure-outcome relationship, we used a generalized linear mixed model with a Poisson distribution to model the number of CLABSIs. Results: During 1,837,750 patient-days, 283,087 patients, used 1,218,882 CL-days. CLABSI per 1,000 CL-days rates decreased from 15.34 at the baseline period to 7.97 in the 2nd month (relative risk (RR) = 0.52; 95% confidence interval [CI] = 0.48-0.56; P < .001), 5.34 in the 3rd month (RR = 0.35; 95% CI = 0.32-0.38; P < .001), and 2.23 in the 17 to 29 months (RR = 0.15; 95% CI = 0.13-0.17; P < .001). In-ICU all-cause mortality rate decreased from 16.17% at baseline to 13.68% (RR = 0.84; P = .0013) at 17 to 29 months. Conclusions: The implemented approach was effective, and a similar intervention could be applied in other ICUs of low- and middle-income countries to reduce CLABSI and in-ICU all-cause mortality rates.
AB - Background: Central line (CL)-associated bloodstream infections (CLABSIs) occurring in the intensive care unit (ICU) are common and associated with a high burden. Methods: We implemented a multidimensional approach, incorporating an 11-element bundle, education, surveillance of CLABSI rates and clinical outcomes, monitoring compliance with bundle components, feedback of CLABSI rates and clinical outcomes, and performance feedback in 316 ICUs across 30 low- and middle-income countries. Our dependent variables were CLABSI per 1,000-CL-days and in-ICU all-cause mortality rates. These variables were measured at baseline and during the intervention, specifically during the second month, third month, 4 to 16 months, and 17 to 29 months. Comparisons were conducted using a two-sample t test. To explore the exposure-outcome relationship, we used a generalized linear mixed model with a Poisson distribution to model the number of CLABSIs. Results: During 1,837,750 patient-days, 283,087 patients, used 1,218,882 CL-days. CLABSI per 1,000 CL-days rates decreased from 15.34 at the baseline period to 7.97 in the 2nd month (relative risk (RR) = 0.52; 95% confidence interval [CI] = 0.48-0.56; P < .001), 5.34 in the 3rd month (RR = 0.35; 95% CI = 0.32-0.38; P < .001), and 2.23 in the 17 to 29 months (RR = 0.15; 95% CI = 0.13-0.17; P < .001). In-ICU all-cause mortality rate decreased from 16.17% at baseline to 13.68% (RR = 0.84; P = .0013) at 17 to 29 months. Conclusions: The implemented approach was effective, and a similar intervention could be applied in other ICUs of low- and middle-income countries to reduce CLABSI and in-ICU all-cause mortality rates.
KW - Antibiotic resistance
KW - Developing countries
KW - Device-associated infection
KW - Health care–associated infection
KW - Hospital infection
KW - Limited resources countries
KW - Low income countries
KW - Network
KW - Nosocomial infection
UR - https://www.scopus.com/pages/publications/85184737909
U2 - 10.1016/j.ajic.2023.12.010
DO - 10.1016/j.ajic.2023.12.010
M3 - Artículo
C2 - 38154739
AN - SCOPUS:85184737909
SN - 0196-6553
VL - 52
SP - 580
EP - 587
JO - American Journal of Infection Control
JF - American Journal of Infection Control
IS - 5
ER -